COVID-19 in Patients With Hematological Malignancies: Considering the Role of Tyrosine Kinase Inhibitors

In an article previously published in Cancer, Cattaneo et al. analyzed a cohort of patients with coronavirus disease 2019 (COVID-19) and hematological malignancies in March 2020, and they highlighted that subjects with chronic myeloid leukemia (CML) had a lower than expected frequency of COVID-19. The authors linked this observation to the lower level of immunodeficiency seen in CML and to a potential protective role of tyrosine kinase inhibitors (TKIs) based on the possible antiviral activity of these drugs. However, they reported a mortality rate 30 days after the documentation of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of 50% in the group of patients with chronic myeloproliferative malignancies, which included patients with CML (78% of these patients were treated with TKIs).

As the authors insightfully pointed out in their article, imatinib (the main TKI for CML treatment) has shown antiviral effects against other betacoronaviruses in vitro studies, probably by preventing virus entry into host cells via interference with the fusion between viral and cellular membranes. Regarding SARS-CoV-2, there are conflicting data about the antiviral potential of this drug; although significant suppression of viral replication in Vero E6 cells has been described, no potent effect over the virus lifecycle in Caco-2 cell cultures has been recently reported with the standard dosage of imatinib (400–800 mg/d).

Furthermore, imatinib might exert its potential protective role in COVID-19 through its immunomodulatory properties. Murine models of sepsis and acute lung injury have suggested that this drug has a beneficial effect by reducing pulmonary edema, preventing histological damage, and improving endothelial barrier integrity, probably by attenuating the release of proinflammatory cytokines, including interleukin 6 and tumor necrosis factor α. This cytokine downregulation has also been observed in patients with CML and seems to be mediated by the inhibition of transcription factor NF-κB according to previous evidence from animal and human cell studies. This is particularly interesting because the NF-κB pathway has been pointed out as one of the main inflammatory signaling cascades leading to the pulmonary damage observed in severe COVID-19. In this regard, both a lower incidence and a lower severity of this condition have been consistently reported in subjects with CML. In fact, Passamonti et al. have recently found that all patients with CML under TKI treatment in their Italian multicenter cohort of hematological patients with a SARS-CoV-2 infection were alive at the end of follow-up.

In conclusion, we consider that the positive outcomes of TKI-treated CML patients with COVID-19, including a lower frequency of SARS-CoV-2 infection and a higher survival rate, strengthen the hypothesis that these drugs might be beneficial in the treatment of this disease. Hence, we believe that a more detailed description by Cattaneo et al. about deceased subjects with CML under TKI therapy in their study would be valuable. Finally, further clinical research should be encouraged to assess the effectiveness of imatinib and other related TKIs in COVID-19.

FUNDING SUPPORT
No specific funding was disclosed.

CONFLICT OF INTEREST DISCLOSURES
Miguel Ángel Canales-Albendea declares consulting fees from Novartis. David Bernal-Bello is the principal investigator of a nonsponsored randomized trial investigating the therapeutic role of imatinib and baricitinib in patients with coronavirus disease 2019 (NCT04346147); Alejandro Morales-Ortega, Begoña Frutos-Pérez, Beatriz Jaenes-Barrios, and Ana Isabel Farfán-Sedano are subinvestigators of this project. The other author made no disclosures.

REFERENCES
1. Cattaneo C, Daffini R, Pagani C, et al. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer. 2020;126:5069-5076. doi:10.1002/cncr.33160
2. Sisk JM, Frieman MB, Machamer CE. Coronavirus S protein–induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J Gen Virol. 2018;99:619-630. doi:10.1099/jgv.0.001047
3. Coleman CM, Sisk JM, Mingo RM, et al. Abelosin kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J Virol. 2016;90:8924-8933. doi:10.1128/JVI.01429-16
4. Sauvat A, Ciccosanti F, Colavita F, et al. On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2. Cell Death Dis. 2020;11:656. doi:10.1038/s41419-020-02842-x
5. Zhao H, Mendenhall M, Deininger MW. Imatinib is not a potent anti–SARS-CoV-2 drug. Leukemia. Published online September 30, 2020. doi:10.1038/s41375-020-01045-9
6. Bernal-Bello D, Jaenes-Barrios B, Morales-Ortega A, et al. Imatinib might constitute a treatment option for lung involvement in COVID-19. Autoimmun Rev. 2020;19:102565. doi:10.1016/j.autrev.2020.102565
7. Rizzo AN, Sammani S, Esquinca AE, et al. Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. *Am J Physiol Lung Cell Mol Physiol*. 2015;309:L1294-L1304. doi:10.1152/ajplung.00331.2015

8. Stephens RS, Johnston L, Servinsky L, et al. The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice. *Physiol Rep*. 2015;3:e12589. doi:10.14814/phy2.12589

9. Ciarcia R, Vitiello MT, Galdiero M, et al. Imatinib treatment inhibits IL-6, IL-8, NFKB and AP-1 production and modulate intracellular calcium in CML patients. *J Cell Physiol*. 2012;227:2798-2803.doi:10.1002/jcp.23029

10. Dosch SF, Mahajan SD, Collins AR. SARS coronavirus spike protein–induced innate immune response occurs via activation of the NF-κB pathway in human monocyte macrophages in vitro. *Virus Res*. 2009;142:19-27.doi:10.1016/j.virusres.2009.01.005

11. Ingraham NE, Lofri-Emran S, Thielen BK, et al. Immunomodulation in COVID-19. *Lancet Respir Med*. 2020;8:544-546.doi:10.1016/S2213-2600(20)30226-5

12. Li W, Wang D, Guo J, et al. COVID-19 in persons with chronic myeloid leukaemia. *Leukemia*. 2020;34:1799-1804.doi:10.1038/s41375-020-0853-6

13. Breccia M, Abruzzese E, Bocchia M, et al. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. *Leukemia*. 2020;34:2260-2261.doi:10.1038/s41375-020-0094-z

14. García-Suarez J, de la Cruz J, Cedillo A, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. *J Hematol Oncol*. 2020;13:133. doi:10.1186/s13045-020-00970-7

15. Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. *Lancet Haematol*. 2020;7:e737-e745.doi:10.1016/S2352-3026(20)30251-9

Alejandro Morales-Ortega, MD
Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain

Jaime García de Tena, MD, PhD
Department of Medicine, Universidad de Alcalá, Madrid, Spain

Begoña Frutos-Pérez, MD
Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain

Beatriz Jaenes-Barrios, MD
Castilla La Nueva Primary Health Care Center, Madrid, Spain

Ana Isabel Farfán-Sedano, MD
Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain

Miguel Ángel Canales-Albendea, MD, PhD
Department of Hematology, Hospital Universitario La Paz, Madrid, Spain

David Bernal-Bello, MD, PhD
Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain

DOI: 10.1002/cncr.33432, Published online March 15, 2021 in Wiley Online Library (wileyonlinelibrary.com)